Subscribe to RSS
Download PDF
DOI: 10.1055/s-0037-1613093
Evaluation of Potential Antigenicity of Active-Site-Inhibited Recombinant Human FVIIa (FFR-rFVIIa) in an Immune-Tolerant Rat Model
Authors
Publication History
Received
08 October 2001
Accepted after revision
22 January 2002
Publication Date:
11 December 2017 (online)
Summary
Recombinant human FVIIa (rFVIIa) was inactivated by coupling Phe-Phe-Arg-CO- (FFR) covalently to the active site of the enzyme. To test the chemically-modified human protein for potential antigenicity prior to clinical trial an immune-tolerant rat model was established. Intraperitoneal injection of the parent compound, human rFVIIa, within 30 h after birth, followed by repeated subcutaneous challenge with rFVIIa in Freunds incomplete adjuvant resulted in 79% non-responding rats at day 32. Monthly subcutaneous challenge showed that the induced tolerance was stable over the 3 months study period in 80% of the rats. The clinically relevant route, intravenous administration, was used for evaluating the potential antigenicity of FFR-rFVIIa. Repeated intravenous administration of different dosages of FFR-rFVIIa did not break tolerance, indicating that FFR-rFVIIa might not be antigenic, for a limited number of intravenous administrations in a clinical setting.
-
References
- 1 Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, Hedner U. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27 (20) 7785-93.
- 2 Sorensen BB, Persson E, Freskgard PO, Kjalke M, Ezban M, Williams T, Rao LV. Incorporation of an active site inhibitor in Factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272 (18) 11863-8.
- 3 Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26 (Suppl. 01) 76-82.
- 4 Golino P, Ragni M, Cirillo P, D’Andrea D, Scognamiglio A, Ravera A, Buono C, Ezban M, Corcione N, Vigorito F, Condorelli M, Chiariella M. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circulation Research 1998; 82 (01) 39-46.
- 5 Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19 (02) 163-76.
- 6 Nicolaisen EM, Hansen LH, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost 1996; 76 (02) 200-4.
- 7 Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood coagulation and fibrinolysis 1998; 09 (Suppl. 01) S119-23.
- 8 Rapaport SI, Rao LV. The tissue factor pathway: how it has become a “prima ballerina”. Thromb Haemost 1995; 74 (01) 7-17.
- 9 Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92 (10) 3041-50.
- 10 Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombastenia. Blood 2000; 94 (11) 3951-3.
- 11 Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Igchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand’s disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (Suppl. 01) 150-4.
- 12 Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 1989; 06: 275-281.
- 13 Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA 1998; 95: 5734-9.
- 14 Laulan A, Sauger A, Germain C, Montembault A-M, Sans I, Potentini-Esnault C, Chicane G, Sultan Y, Bartholeyns J. Frequency of human anti-FVIII antibodies in humanized SCID mice elicited by recombinant deleted factor VIII and by plasma derived factor VIII. J Immunol Meth 1997; 210: 205-14.
- 15 Pittman DB, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, Immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-35.